Startek® Wins 2025 Fortress Cybersecurity Award for Organizational Excellence
The Fortress Cybersecurity Awards program honors the industry's leading companies and professionals who go beyond compliance to establish and maintain secure operations. Winners are selected based on innovation, measurable impact and a steadfast commitment to security best practices.
"This award reinforces our core philosophy that cybersecurity and CX excellence are inseparable," said Abhinandan Jain, Chief Growth Officer of Startek. "We've integrated AI-powered tools, processes and protocols into every transaction allowing us to proactively prevent threats without compromising the human connection to deliver personalized experiences at scale."
"The volume and complexity of threats facing organizations today is growing by the minute," said Russ Fordyce, CEO of the Business Intelligence Group. "The winners of this year's Fortress Cybersecurity Awards are not only keeping up—they're setting the pace. We're proud to honor Startek for building systems and solutions that make us all more secure."
Startek was recognized for its robust cybersecurity frameworks and integrated risk management practices, ensuring operational resilience while supporting clients' business goals.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives with real-world experience. The organization's proprietary scoring system measures performance across multiple business domains and rewards companies whose achievements are significant and measurable.
About Startek
Startek ® is a global leader in customer experience management, delivering comprehensive digital transformation and CX solutions. With over 35 years of expertise, Startek empowers businesses across diverse industries to create memorable personalized customer interactions. Operating in 12 countries with a team of 38,000 associates, Startek is committed to connecting brands with their customers through innovation, empathy and operational excellence.
To learn more, visit www.startek.com and follow us on LinkedIn @Startek.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
MEDIA ADVISORY - RF CAPITAL TO REPORT SECOND QUARTER 2025 RESULTS JULY 31, 2025
TORONTO, July 4, 2025 /CNW/ - RF Capital Group Inc. (RF Capital) (TSX: RCG) is scheduled to release its second quarter 2025 financial results on Thursday, July 31, 2025, after market close. An earnings conference call and live audio webcast will be held on Friday, August 1 at 10:00 a.m. (EST). The call will be hosted by Dave Kelly, President and Chief Executive Officer, and Francis Baillargeon, Chief Financial Officer, followed by a question-and-answer period with investment analysts. Interested parties are invited to access the first quarter earnings conference call on a listen-only basis by dialing 416-406-0743 or 1-800-898-3989 (toll free) and entering participant passcode: 3903524#. The conference call will also be accessible as a live audio webcast through the Investor Relations section of the Company's website at A recording of the conference call will be available until Sunday, August 31, 2025, by dialing 905-694-9451 or 1-800-408-3053 (toll free) and entering access code 2356231#. The webcast will be archived at ABOUT RF CAPITAL GROUP INC. RF Capital Group Inc. is a TSX-listed (TSX: RCG) wealth management-focused company. Operating under the Richardson Wealth brand, the Company is one of the largest independent wealth management firms in Canada with $40.3 billion in assets under administration (as of June 30, 2025) and 23 offices across the country. The firm's Advisor teams are focused exclusively on providing strategic wealth advice and innovative investment solutions customized for high net worth or ultra-high net worth families and entrepreneurs. The Company is committed to maintaining exceptional fiduciary standards and has earned certification – determined annually – from the Centre for Fiduciary Excellence for its Separately Managed and Portfolio Management Account platforms. For the seventh year, Richardson Wealth has been certified as a "great place to work" by Great Place to Work®, a global authority on workplace culture. To learn more about the Company, please visit and to view our 2024 annual report and our latest recruiting brochure. SOURCE RF Capital Group Inc.
Cision Canada
6 hours ago
- Cision Canada
Mowilex models environmental leadership with new Cikande factory solar panels: for every 4 liters of Mowilex paint, 1 is now powered by the sun
With new solar panels at its Cikande factory, Mowilex has expanded its commitment to renewable energy, efficiency and the environment. The installation will lower the company's carbon footprint and cut grid electricity use by up to 25% per year. Mowilex earned its sixth consecutive CarbonNeutral® company certification in late 2024, and further supports Indonesia's clean energy goals with this solar project. JAKARTA, Indonesia, July 4, 2025 /CNW/ -- With the installation of solar panels at its Cikande factory, PT Mowilex Indonesia (Mowilex) is expanding its long-standing commitment to clean, renewable energy. Mowilex was Indonesia's first paint company to make major solar investments, demonstrating environmental leadership by first installing panels at its corporate headquarters in 2022. Over 500 solar modules now cover the roof of the main Cikande factory building. Another 252 solar modules were installed on car and motorcycle parking canopies. The system will reduce grid electricity use at the company's Cikande factory by approximately 500 kilowatt-hours (kWh) annually – and that means 1 of every 4 liters produced will be made with renewable energy. With the Cikande solar panels, Mowilex will lower its operational carbon footprint and cut non-renewable energy use by up to 25% per year. The company's new renewable energy project advances Indonesia's clean energy goals and comes just months after Mowilex earned its sixth consecutive CarbonNeutral® company certification. "We believe in taking real action to decarbonize. This solar installation at our Cikande factory goes beyond buying offsets, and it's more than a technological upgrade. It is a reflection of our core values. As a company rooted in environmental responsibility, this initiative brings us one step closer to a cleaner future for Indonesia," says Niko Safavi, CEO of PT Mowilex Indonesia. Through its investment in solar projects, Mowilex is actively reducing its dependence on brown energy. In contrast to brown energy, derived from fossil fuels and associated with high emissions and environmental harm, green energy represents a cleaner, renewable alternative. This strategic transition enables Mowilex to adopt a more stable, self-sufficient and environmentally responsible energy solution. The expanded use of solar also aligns with the environmental and ethical expectations of Indonesian consumers. Climate change worries 87% of Indonesians, says the global communications firm Edelman, and more than 90% of Indonesians think businesses don't do enough engagement around climate change issues. Another 90% expect CEOs to take a public stance on climate change. Mowilex embraces the opportunity to educate and deliver solutions to climate challenges through its products and practices. "We see consumers shifting their purchasing power toward brands that actively work to mitigate climate change. Mowilex is proud to meet those market expectations," says Safavi. "Solar is a reliable, independent power source that contributes to our energy security and supports Indonesia's renewable energy policies. By making this long-term investment, we hope to be a model for industry and for the greater public." PT Mowilex Indonesia (Mowilex), a subsidiary of Asia Coatings Enterprises, Pte. Ltd., is a leading producer of premium paints and coatings. Since launching the first Indonesian-made, water-based paints in 1970, the company has expanded its commitment to environmental ethics, equality, community and innovation. PT Mowilex is Indonesia's only certified carbon neutral manufacturer, producing zero and low VOC paints in modern colours, and the company regularly wins awards for its corporate social responsibility and sustainability efforts. Media contact: [email protected] Visit the Mowilex website for product and sustainability information.
Cision Canada
a day ago
- Cision Canada
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY Français
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY ® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy. "This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia," said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. "These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need." New longer-term follow-up data presented from the CASGEVY trials In SCD, 43/45 (95.6%) evaluable patients (those with at least 16 months of follow-up) were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months (VF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 84.9%, 99.5%). The mean duration of VOC-free was 35.0 months (range 14.4 to 66.2 months). All evaluable patients (45/45 [100%]) achieved freedom from in-patient hospitalization for severe VOCs for at least 12 consecutive months (HF12) in CLIMB-121 and CLIMB-131 combined (95% CI: 92.1%, 100%), with a mean hospitalization-free of 36.1 months (range 14.5 to 66.2 months). In TDT, 54/55 (98.2%) evaluable patients (those with at least 16 months of follow-up) achieved transfusion-independence for at least 12 consecutive months with a weighted average hemoglobin (Hb) of at least 9 g/dL (TI12) in CLIMB-111 and CLIMB-131 combined (95% CI: 90.3%, 100%). The mean duration of transfusion independence was 40.5 months (range 13.6 to 70.8 months). The one evaluable patient who did not achieve TI12 has been transfusion free for 14.8 months. Iron removal therapy has been stopped for more than 6 months in 39/56 (69.6%) treated patients following infusion with CASGEVY, with sustained improvement in ferritin and liver iron content, suggesting that CASGEVY has the potential to correct ineffective erythropoiesis. Patients continue to demonstrate stable levels of fetal hemoglobin (HbF) and allelic editing. The safety profile of CASGEVY continues to be generally consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. Progress in bringing CASGEVY to patients Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales. In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending. Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or "sickled" red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Pr CASGEVY ® (exagamglogene autotemcel) Pr CASGEVY ® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Media: [email protected] orCanada: +1 647-790-1600orU.S.: 617-341-6992 SOURCE Vertex Pharmaceuticals (Canada) Inc.
